Original Research Paper

TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation

Ying Shen\textsuperscript{a,1}, Xiaoyue Wei\textsuperscript{a,b,1}, Shijie Jin\textsuperscript{a}, Yue Wu\textsuperscript{d}, Wenbin Zhao\textsuperscript{a}, Yingchun Xu\textsuperscript{a}, Liqiang Pan\textsuperscript{a}, Zhan Zhou\textsuperscript{a}, Shuqing Chen\textsuperscript{a,∗}

\textsuperscript{a} College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
\textsuperscript{b} Huabo Biopharm Co., Ltd., Shanghai 201203, China

\textbf{A B S T R A C T}

Limited clinical application of antibody-drug conjugates (ADCs) targeting tumor associated antigens (TAA)s is usually caused by on-target off-tumor side effect. Tumor-specific mutant antigens (TSMAs) only expressed in tumor cells which are ideal targets for ADCs. In addition, intracellular somatic mutant proteins can be presented on the cell surface by human leukocyte antigen class I (HLA I)molecules forming tumor-specific peptide/HLA I complexes. KRAS G12V mutation frequently occurred in varied cancer and was verified as a promising target for cancer therapy. In this study, we generated two TCR-mimic antibody-drug conjugates (TCRm-ADCs), 2E8-MMAE and 2A5-MMAE, targeting KRAS G12V/HLA-A*0201 complex, which mediated specific antitumor activity in vitro and in vivo without obvious toxicity. Our findings are the first time validate the strategy of TCRm-ADCs targeting intracellular TSMAs, which improves the safety of antibody-based drugs and provides novel strategy for precision medicine in cancer therapy.

© 2020 Shenyang Pharmaceutical University. Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. \textbf{Introduction}

Antibody-drug conjugates (ADCs) are a novel class of antitumor therapeutics that combine antigen-targeting monoclonal antibodies (mAbs) with potent cytotoxic drugs via stable linkers. Thus, they can bring drugs specifically into tumor, which effectively improve the drug concentration in the tumor sites, and greatly reduces the drug concentrations in other tissues to expand the therapeutic window of drugs.

At present, dozens of ADCs have entered clinical studies and seven of them have been approved by the Food and Drug Administration (FDA) or European Medicines Agency (EMA) [1]. However, ADCs are mainly targeted tumor associated antigens (TAA)s. Although TAA}s are highly expressed in tumor cells, there are also with low level of expression in some normal cells, resulting the on-target off-tumor side effect during the long period in circulation, which limits the clinical application of ADCs (Fig. 1) [2].

\textsuperscript{∗} Corresponding author. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Tel.: +86 571 88208411
E-mail address: chenshuqing@zju.edu.cn (S.Q. Chen).
\textsuperscript{1} Both authors contribute equally to this work.
Peer review under responsibility of Shenyang Pharmaceutical University.

https://doi.org/10.1016/j.ajps.2020.01.002
1818-0876 © 2020 Shenyang Pharmaceutical University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Tumor specific mutant antigens (TSMAs) expressed particularly in tumor cells, however, most of them are located inside the tumor cells and thus not accessible to current marketed therapeutic mAbs or ADCs [3,4]. Major histocompatibility complex class I (MHC I), also known as human leukocyte antigen class I (HLA I) in human beings, is capable of presenting peptides derived from intracellular tumor associated proteins or somatically mutant proteins on cell surface, forming a peptide/MHC I complex as TAA or TSMAs for T cell receptor (TCR) and TCR-mimic (TCRm) antibody recognition (Fig. 1) [5,6].

KRAS oncoprotein is a GTPases in regulating pathways, which is responsible for cell survival and proliferation [7]. KRAS is frequently mutated in a variety of cancers, including pancreatic cancer (~90%), colon cancer (~43%), lung cancer (~30%), and melanoma (~50%). Aberrant KRAS is involved in cell proliferation and differentiation, and is associated with a single mutation typically at codon 12, 13 or 61, especially at codon 12 (80%). KRAS mutation patterns are dominated by G to T transitions at the second base of codons 12 resulting in G12V mutation, G to A transitions at the second base of codons 12 or 13 make up the bulk of the remainder to produce G12D or G13D and G to T transitions of the first base of codon 12 to produce G12C mutations [8]. The 10-mer KRAS mutation-derived peptide, KLVVGAGGV (G12V) and KLVVGADGV (G12D), has been shown to be presented by HLA-A*0201 molecules that induces cytotoxic CD8+ T cells to kill KRAS mutant tumor cells [9-12]. At present, TCRm antibody targeting KRAS G12V/HLA-A*0201 has only been reported by Skora and his colleagues [13], but research on TCR-mimic antibody-drug conjugates (TCRm-ADCs) targeting KRAS G12V/HLA-A*0201 for tumor targeted therapy has not been reported yet.

In this paper, we sought out to study the design of novel-target TCRm-ADCs, hoping to expand the application of ADCs and improve ADCs’ safety. To study the novel-target TCRm-ADCs based on TSMAs presented by HLA I, we selected the KRAS G12V/HLA-A*0201 complex as a target. We generated the TCRm antibodies (2A5 and 2E8) by genetic engineering technology and comprehensively evaluated the properties of TCRm-ADCs (2A5-MMAE and 2E8-MMAE), including binding affinity, internalization, and antitumor activities in vitro and in vivo.

2. Materials and methods

2.1. Cell lines and reagents

T2 cell line and CHO-K1 cell line were purchased from the American Type Culture Collection (ATCC, San Francisco, USA). K562 cell line and SW480 cell line were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). T2 cell line was grown in IMDM medium (Gibco, life technologies) supplemented with 20% FBS (Gibco, life technologies). K562 cell line and SW480 cell line was cultured in RPMI-1640 medium (Gibco, life technologies) supplemented with 10% FBS. Cell lines were maintained in a humid atmosphere at 37°C and 5% CO2 with 100 U/ml penicillin, and 100 μg/ml streptomycin. Maleimidocaproyl-valine-citulline-monomethyl auristatin E (Mal-Val-Cit-MMAE) were synthesized by Levena Biopharm.
(Nanjing, Jiangsu, China). All reagents were purchased from Sigma-Aldrich (Saint Louis, MO, USA) unless otherwise noted.

2.2. Animals

Female BALB/c nude mice (6–8 weeks old) were purchased from Sangon Biotech (Shanghai, China) and were housed in a specific pathogen free facility. All animal experiments were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. The protocols were approved by the Committee on the Ethics of Animal Experiments of the Zhejiang University, China (ZJU20170435).

2.3. Preparation of TCRm antibody (2G1) and its variants (2A5 and 2E8)

The anti-KRAS G12V/HLA-A*0201 single-chain antibody was selected as previously described [13] and further engineered into a human IgG1 frame to generate a full human antibodies named 2G1. Briefly, the DNA sequences of anti-KRAS G12V/HLA-A*0201 single-chain antibody variant region were synthesized by Sangon Biotech (Shanghai, China) and inserted into the pFUSE2-CLigK and pFUSE-CHig-hG1 plasmids (InvivoGen, USA) for expressing full-length human heavy and light chains respectively. To facilitate the sitespecific conjugation of MMAE, cysteine mutations were introduced in heavy chain (A114C) and light chain (V205C) by overlap PCR and inserted into the pFUSE2-CLigK and pFUSE-CHig-hG1 plasmids. For the expression of TCRm antibodies, relevant expression plasmids were stably transfected into CHO-K1 cells (ATCC, USA). TCRm antibodies were purified by protein A antibody affinity chromatography (HiTrap Protein A HP column, GE) and stored at –80°C.

2.4. Preparation of TCRm-ADCs

To optimize the reaction conditions of the chemical site-specific conjugation, the reaction molar ratio of TCRm antibody to Mal-Val-Cit-MMAE and the reaction time were explored. TCRm antibodies (2E8 or 2A5) was buffer exchanged into 50 mM phosphate-buffered solution (PBS) containing 10 mM EDTA, pH 7.4, and diluted to a final concentration of 3–5 mg/mL. 50-fold molar equivalents of Tris (2-carboxyethyl)phosphine Hydrochloride (TCEP-HCl) were added to the solution. The reaction mixture was reduced at 37°C for 3 h to disrupt intermolecular disulfide bond and TCEP was removed by ultrafiltration (Amicon Ultra-0.5 ml 30 KD, Millipore) using 50 mM PBS (10 mM EDTA), pH 7.4. Then 20-fold molar equivalents of dehydroascorbic acid (DHAA) were added to the reduced antibody. After incubating at room temperature (RT) for 3 h, 2-fold, 4-fold, 6-fold, 8-fold, 10-fold or 15-fold molar equivalents of Mal-Val-Cit-MMAE were added. The reaction was mixed on a rotator gently at RT for 1.5 h or 3 h. The crude TCRm-ADCs were buffer exchanged into PBS to remove unconjugated payloads via centrifugal ultrafiltration.

2.5. Characterization of TCRm antibodies and TCRm-ADCs

To analysis of potential TCRm antibodies and TCRm-ADCs aggregation, we applied a silica-based Tosoh TSKgel G3000SWXL size exclusion column (SEC, 7.8 mm × 30 cm dimension, 5 μm particle size, 250 Å pore size) to separate monomer and aggregate with mobile phase (300 mM NaCl, 50 mM Na2HPO4, pH 7.2), at flow rate of 1 mL/min. Reversed phase high performance liquid chromatography (RP-HPLC) was performed using the Agilent PLRP-S column (100 Å, 8 μm, 2.1 mm × 150 mm) to evaluate conjugation efficiencies as previously described [14].

In order to determine the drug to antibody ratio (DAR), hydrophobic interaction chromatography (HIC) was performed on a Tosoh Butyl-NPR column (2.5 μm, 4.6 mm × 3.5 cm) to separate TCRm-ADCs with different DAR at 0.8 mL/min with a 15 min linear gradient elution from 1.5 M (NH4)2SO4, 25 mM Na2PO4 (pH 7.0) to 25 mM Na2PO4 (pH = 7.0), 25% isopropanol. To further characterize the conjugation site, trypsin digested TCRm-ADCs fragments were analyzed by Waters UPLC Acquity Bio H Class equipped Xevo G2-S Q TOF as previously described [15].

2.6. Binding affinity and specificity of TCRm antibodies and TCRm-ADCs

T2 cell line is an HLA-A*0201 positive cell line that lacks transporter-associated protein (TAP), which allows for efficient loading of endogenous peptides. Hence, only empty HLA-A*0201 exists on cell surface which can carry exogenous TCR epitope peptides [16]. T2 cells were cultured at 5 × 10⁶ cells/mL in serum-free IMDM with 50 μg/mL peptide (G12V, G12D or wildtype (WT)) and 10 μg/mL human beta-2 microglobulin (β2m, Sigma) overnight at 37°C, 5% CO2, and T2 cells only incubated with β2m were set as negative control. Cells were collected and washed twice with ice-cold PBS, then resuspended with 10 μg/mL TCRm antibodies or TCRm-ADCs in 1%BSA-PBS and incubated on ice for 30 min. After that, cells were washed twice with ice-cold PBS and stained by goat anti-human IgG (H+L)-FITC antibodies (Beyotime Biotechnology) on ice for 30 min. After twice ice-cold PBS wash, mean fluorescence intensity (MFI) of stained cells was measured by a Cytomix FC500 MCL flow cytometer (Beckman Coulter).

2.7. In vitro efficacy of TCRm-ADCs

The cytotoxicity of 2A5-MMAE and 2E8-MMAE was assessed on SW480, K562, K562-A2 and K562-A2 HUP cell lines. Briefly, cells were seeded at a density of 4 × 10⁵ cells/100 μl/well in 96-well cell culture plates (Corning), SW480 and K562-A2 were treated with 20 μg/mL or 50 μg/mL of G12V peptide as positive controls. After overnight culture, cells were incubated with serial concentrations of 2A5-MMAE and 2E8-MMAE (3 replicates per concentration) at 37°C, 5% CO2 for 96 h. Cell viability was measured by Cell Counting Kit-8 (CKK-8,
2.8. Cellular internalization of TCRm-ADCs

To quantitatively evaluate the internalization of 2A5-MMAE and 2E8-MMAE, K562-A2 HUP cells in parallel were incubated with 10 μg/ml 2A5-MMAE or 2E8-MMAE on ice for 30 min and washed twice with ice-cold PBS. Subsequently, cells were incubated at 37 °C or 4 °C for 2.5 h and washed twice with ice-cold PBS. Then, cells were stained by Cy5-labeled Goat Anti-Human IgG (H+L) polyclonal antibody (Abcam, UK) on ice for 30 min. After twice ice-cold PBS wash, MFI of stained cells was measured by flow cytometer as above. Cellular internalization ratio (%) = (MFI of 4 °C - MFI of 37 °C)/MFI of 4 °C × 100%. For the assessment of cellular trafficking of 2A5-MMAE and 2E8-MMAE by confocal microscopy, 2 × 10⁴ K562-A2 HUP cells were seeded on slides and treated with 10 μg/ml 2A5-MMAE or 2E8-MMAE for 6 h. Subsequent cell fixation and staining were performed as previously described [17]. Briefly, cells were fixed with 4% paraformaldehyde for 15 min and were permeabilized with 0.1% Triton X-100, 0.2% BSA in PBS for 10 min, followed by 2% BSA-PBS blocking for 30 min. Then, cells were incubated with rabbit anti-human lysosome antibody (Abcam) in 1% BSA-PBS for 45 min. After that, cells were stained with Cy3-labeled Goat Anti-Rabbit IgG (H+L) polyclonal antibody (Beyotime, China) and Cy5-labeled Goat Anti-Human IgG (H+L) polyclonal antibody for 45 min. Nuclei were further stained with DAPI (Beyotime) for 3 min. PBS washing was necessary after each staining. Then, cells were covered with coverslip and fluorescence images were acquired by DU-897D-CS0 rotary confocal laser scanning microscopy.

2.9. In vivo antitumor activity and toxicity of TCRm-ADCs in mouse xenograft study

BALB/c nude mice were pretreated with cyclophosphamide (i.p.) at a dose of 50 mg/kg for 2 d 1 × 10⁷ K562-A2 HUP cells in 100 μl PBS and 100 μl of matrigel (Corning) were subcutaneously injected into the right flank of nude mice. 8 d after inoculation, the mice were randomly divided into 3 groups with 6 mice per group: PBS, ofatumumab (OFA)-MMAE (20 mg/kg) and 2A5-MMAE (20 mg/kg). Each group was treated (i.v.) once every 4 d for four times (q4d × 4). The body weight and tumor volume (V = (L × W²)/2, L is length and W is width of tumor) were monitored using callipers and an electronic balance, respectively, every 4 d. Twenty-four hours after the fourth administration, the possible acute toxicity in heart, liver, kidney or spleen was examined by morphological examination through hematoxylin and eosin (H&E) staining.

2.10. Statistical analysis

T-test was used to determine statistical significance, P < 0.05 was considered statistically significant.

3. Results and discussion

3.1. Preparation and characterization of TCRm antibody 2G1 and its variants against KRAS G12V/HLA-A*0201

2E8 and 2A5 were the variants of 2G1, which 2E8 was heavy chain A114C mutation and 2A5 was light chain V205C and heavy chain A114C mutation, for site-specific conjugation (Fig. 2A, S1). 2G1, 2E8 and 2A5, against KRAS G12V/HLA-A*0201 complex, were successfully expressed by CHO-K1 cells. The variants retained the monomer structure with similar molecular weights (Fig. 2B). We verified the binding affinity and specificity of 2G1 and its variants via T2 cells incubated with β2m and peptide. As showed in Fig. 3A, these three TCRm antibodies can bind to the KRAS G12V/HLA-A*0201 presented on the surface of T2 cells, and we unexpectedly found that the 2A5 had a significantly higher affinity for the KRAS G12V/HLA-A*0201 than that of 2G1 and 2E8. At the same time, its binding specificity retained that 2A5 did not recognize KRAS G12D/HLA-A*0201 and KRAS W7/HLA-A*0201 (Fig. 3D). The cysteine engineered at different site generated various of TCRm antibodies with different binding affinity. That’s to say, single mutation of TCRm antibody, even on constant region of heavy and light chains, has a significant influence on the binding affinity. We also

Fig. 2 – Preparation and characterization of TCRm antibodies 2G1 and its variants against KRAS G12V/HLA-A*0201. (A) Schematic representation of 2G1 human full-length antibody and its variants. LC: light chain; HC: heavy chain; 2E8: LC+HC A114C; 2A5: LC V205C+HC A114C. Red lines in heavy chain and light chain indicate the mutant A114C and V205C, respectively. (B) Analysis of the antibodies with size-exclusion chromatography.
evaluated the specificity of 2G1 and 2E8, and found that they specifically recognized KRAS G12V/HLA-A*0201 (Fig. 3B and 3C).

3.2. Preparation and characterization of TCRm-ADCs against KRAS G12V/HLA-A*0201

The random conjugation via lysine amines would lead to the aggregates or binding affinity loss [18]. Site-specific conjugation methods such as sortase A-mediated conjugation, cysteine-maleimide conjugation, chemoenzymatic-mediated conjugation have been tried in antibody conjugations [19,20]. Therefore, we chose the cysteine-maleimide conjugation to generate homogeneous TCRm-ADCs. After conjugation, 2E8-MMAE and 2A5-MMAE were purified by ultrafiltration and analyzed by HPLC. As shown in Fig. 4A, the conjugation efficiency was positively correlated with the molar ratio of antibodies to Mal-Val-Cit-MMAE in a certain content range and an optimal yield was obtained at a molar ratio of 1:10 and reaction for 1.5 h. Further increasing the molar equivalents of Mal-Val-Cit-MMAE and reaction time did not enhance the conjugation efficiency, but increase the production of non-site-specific conjugation products. For example, in the group of 15-fold Mal-Val-Cit-MMAE reaction for 3 h, a small peak appeared after the peak H1, which may be caused by the non-site-specific conjugation of vcMMAE on the TCRm antibodies.

RP-HPLC and HIC were applied to determine the TCRm-ADCs’ DAR. As showed in Fig. 4B and 4C, most 2E8 and 2A5 were modified homogenously, the DAR of 2E8-MMAE and 2A5-MMAE was 1.85 and 3.65, respectively. It showed that TCRm-ADCs were still monomer after conjugated through the SEC analysis (Fig. S2).

Mass spectrometry was used to characterize the conjugation position of 2E8-MMAE and 2A5-MMAE by trypsin digestion (Fig. S3). The molecular weight (Mw) change of the peptide at the conjugation site was consistent with the theoretical value, indicating that vcMMAE was conjugated to the target site. Peptide amino acid sequence and a, b, y ion also determined that vcMMAE was conjugated to cysteine. And daughter ions of m/z 152.1, 321.2, 506.4 and 718.5 were characterization of the vcMMAE, further demonstrating that vcMMAE was efficiently conjugated to 2E8 and 2A5 as expected.

3.3. Binding affinity and specificity of TCRm-ADCs on T2 cell line

To evaluated the change of the binding affinity and specificity of TCRm antibodies after conjugated with vcMMAE, we used T2 cell line for detection. As depicted by Fig. 5A, no detectable affinity loss of 2E8-MMAE was observed by flow cytometry compared with 2E8. And 2E8-MMAE did not bind to KRAS G12D and WT peptide-treated T2 cells, indicating that it retained binding specificity (Fig. 5B). Surprisingly, the binding affinity of 2A5-MMAE was significantly increased compared with 2A5 (Fig. 5C) without specificity loss (Fig. 5D). The enhanced binding affinity of 2A5-MMAE was probably caused by local hydrophobicity increase and antigen-antibody intermolecular interactions promotion after conjugated with vcMMAE.

3.4. In vitro antitumor activities

Barely cytotoxicity was observed on SW480 cell line (HLA-A*0201 and KRAS G12V) when treated with TCRm-ADCs directly, due to extremely low antigen expression on this cell line (the presentation of KRAS G12V/HLA-A*0201 is too low to be detected by flow cytometry and the detection limit of cell surface antigen by flow cytometry is generally 300–500 per cell [21], Fig. S5) under general culture condition in vitro (Fig. 6). Whilst the antitumor activity of TCRm-ADCs improved when SW480 was incubated with G12V peptide, which increased antigens presenting to a detectable level (Fig. 6). We also constructed a K562-A2 HUP cell line, which stably express the ubiquitin-KRAS G12V peptide recombination protein to improve KRAS G12V/HLA-A*0201 presented on the cell surface (Fig. S6) [22]. It turned out that both TCRm-ADCs can exert their cytotoxicity on K562-A2 HUP cells. And the potency of two TCRm-ADCs with DARs of 1.85 or 3.65 was different, i.e. the IC50 of 2A5-MMAE (112.8 nM) was nearly half of the 2E8-MMAE (214.6 nM), suggesting that antitumor activity of TCRm-
ADCs can be enhanced through increasing their payload. Although TCRm-ADCs were still much weaker than other TAA-associated ADCs, that their IC\textsubscript{50} was 700-fold higher compared under the same DAR [20], it can be well tolerated by negative cells (K562) even at a very high concentration of 400 nM (Fig. 6). It demonstrated the highly specificity of 2E8-MMAE and 2A5-MMAE, and that a better antitumor effect can be achieved via increasing antigen presentation on cell surface and DARs of TCRm-ADCs without any cost of safety. Traditional TAAs expression are tens of thousands to hundreds of thousands while the peptide/HLA epitope density is extremely low (dozens to thousands) [23]. Trametinib, a MEK inhibitor, enhanced the efficacy of TCRm-ADCs both in vitro and in vivo through promoting HLA I expression and upregulating the presentation of peptides, which provides strategy to overcome the limitation of TSMAs presentation level for TCRm-ADCs [24]. Besides, cytokine such as TNF-\alpha, IFN-\gamma, GMCSF and IL-2 stimulation also improved the expression of peptide/HLA I on the surface of tumor cells [25–28].

3.5. Internalization of TCRm-ADCs

Flow cytometry was performed to determine the internalization of TCRm-ADCs. As shown in Fig. 7A, approximately 66\% of 2E8-MMAE and 75\% of 2A5-MMAE were internalized by K562-A2 HUP cells respectively after 2.5 h of incubation. The internalization efficiency of 2A5-MMAE was higher than 2E8-MMAE, which might contribute to its antitumor activities.
Fig. 5 – Binding affinity and specificity of the TCRm-ADCs by flow cytometry. (A) Binding affinity of 2E8 and 2E8-MMAE on T2 cells co-incubated with G12V peptide and β2m. (B) Specificity of 2E8-MMAE. (C) Binding affinity of 2A5 and 2A5-MMAE. (D) Specificity of 2A5-MMAE. Ctrl: control, T2 cells co-incubated with G12V peptide and β2m, but without any primary antibody incubated.

Fig. 6 – The in vitro antitumor activity of TCRm-ADCs on K562, SW480 and K562-A2 HUP cell lines. 20 or 50 μg/ml G12V: cells co-incubated with 20 or 50 μg/ml G12V peptide; K562-A2 HUP: K562 cells transfected with HLA-A*0201 and HUP plasmid; 2E8-M: 2E8-MMAE; 2A5-M: 2A5-MMAE.

Furthermore, the subcellular trafficking and localization of 2E8-MMAE and 2A5-MMAE in K562-A2 HUP cells were measured by the confocal microscopy. The overlap of TCRm-ADCs (green fluorescence) and lysosomes (red fluorescence) inside the cells suggested their internalization and co-localization with lysosomes (Fig. 7B). 2A5-MMAE-treated cells showed brighter green fluorescence than 2E8-MMAE, also consistent with that the internalization efficiency of 2A5-MMAE was higher than 2E8-MMAE as shown in flow cytometry.

3.6. In vivo antitumor activities and toxicity of TCRm-ADCs

2A5-MMAE was chosen to validate the antitumor activity and toxicity of TCRm-ADCs targeting intracellular TSMAs in xenograft model since its higher affinity, internalization efficiency and cytotoxicity. As shown in Fig. 8A, 2A5-MMAE (20 mg/kg) significantly inhibited tumor growth even the first dose was administrated when the tumor volume of mice reached 700 mm³. While tumors in the isotype control OFA-
MMAE (20 mg/kg) grew rapidly, which was similar to the tumors in the PBS group, suggesting the specific antitumor efficacy of 2A5-MMAE in vivo.

Toxicity study of TCRm-ADCs was evaluated by the body weight monitoring and histological sections of the major organs. The body weight of treated mice did not change significantly (Fig. 8B) and no obvious histomorphologic alterations were observed in any sections of organs (Fig. 8C) during the administration period, suggesting the safety of TCRm-ADCs. In the later observation period, body weight was losing mostly due to the unbearable pain of tumor growth.

4. Conclusion

In summary, this is the first time that TCRm-ADCs targeting TSMA presented by HLA I have been evaluated in detail. 2E8-MMAE and 2A5-MMAE exhibited highly specific antitumor potential without obvious toxicity. Besides, the development of TCRm-ADCs targeting TSMA represents a promising strategy to decrease the on-target off-tumor effects and improve the safety of ADCs. Furthermore, we demonstrated that intracellular tumor-specific mutation proteins as potential attractive targets in the personalized ADCs field.
Conflicts of interest

The authors report no conflicts of interest.

Acknowledgments

Funding: This work was supported by the National Key Research and Development Program of China ‘Precision Medicine Research’ (Grant No. 2017YFC0908602), the State Key Program of National Natural Science of China (Grant No. 81430081), National Key R&D Program of China (No. 2017YFE0102200).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jajps.2020.01.002.

REFERENCES

[1] de Goey J, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 2016;40:14–23.
[2] Sae S, Aisab HO, Kashaw SK, Titasaip K, Iyer AK. Advances in antibody–drug conjugates: a new era of targeted cancer therapy. Drug Discov Today 2017;22:1547–56.
[3] Weiner LM, Murray JC, Shuprinze OW. Antibody-based immunotherapy of cancer: new insights, new targets. Cell 2012;148:1081–4.
[4] Scott AM, Wolchok JD, Old OL. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278–87.
[5] York IA, Rock KL. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol 1996;14:369–96.
[6] Vyas JM, Van Der Veen AG, Poolch HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008;8:607–18.
[7] McCormick F. ras GTase activating protein: signal transmitter and signal terminator. Cell 1989;56:9–8.
[8] Prior IA, Lewis PD, Mattos C. A comprehensive survey of ras mutations in cancer. Cancer Res 2012;72:2457–67.
[9] Gjertsen MK, Bjørheim J, Sæterdal I, Myklebust I, Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VA) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 1997;72:784–90.
[10] Bergmann Leitner ES, Kantor JA, Shupert WL, Schлом J, Abrams SI. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. Cell Immunol 1998;187:103–16.
[11] Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008;57:1413–20.
[12] Rahma OE, Hamilton JM, Wojtowicz M, Dakhel O, Bernstein S, Liewehr DJ, et al. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med 2014;12:1–12.
[13] Skora AD, Douglass J, Hwang MS, Tam AJ, Blosser RL, Gabelli SB, et al. Generation of MANAbodies specific to HLA-restricted epitopes encoded by somatically mutated genes. Proc Natl Acad Sci 2015;112:9967–72.
[14] Pan LQ, Bin Wang H, Xie ZM, Li ZH, Tang XJ, Xu YC, et al. Novel conjugation of tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) with monomethyl auristatin e for efficient antitumor drug delivery. Adv Mater 2013;25:4718–22.
[15] Pan L, Zhao W, Lai J, Ding D, Zhang Q, Yang X, et al. Sortase A-generated highly potent anti-CD20-MMAE conjugates for efficient elimination of B-lineage lymphomas. Small 2017;13:1–12.
[16] Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985;21:235–46.
[17] Liu W, Zhao W, Bai X, Jin S, Li Y, Qiu C, et al. High antitumor activity of sortase A-generated anti-CD20 antibody fragment drug conjugates. Eur J Pharm Sci 2019;134:81–92.
[18] Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. MAbs 2011;3:164–75.
[19] Wei X, Yang X, Zhao W, Xu Y, Pan L, Chen S. Optimizing multistep delivery of PEGylated tumor-necrosis-factor-related apoptosis-inducing ligand-toxin conjugates for improved antitumor activities. Bioconjug Chem 2017;28:2180–9.
[20] Xu Y, Jin S, Zhao W, Liu W, Ding D, Zhou J, et al. A versatile chemo-enzymatic conjugation approach yields homogeneous and highly potent antibody-drug conjugates. Int J Mol Sci 2017;18:2284.
[21] Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997;6:715–26.
[22] Valmori D, Gieledi U, Servis C, Dunbar PR, Cerottini JC, Romero P, et al. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte–defined peptide derived from the tumor antigen MAGE-3. J Exp Med 2002;189:895–906.
[23] Tao D, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, et al. Targeting the intracellular WT1 oncosene product with a therapeutic human antibody. Sci Transl Med 2013;5:176ra33.
[24] Lai J, Wang Y, Wu SS, Ding D, Sun ZY, Zhang Y, et al. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1. Biomaterials 2018;178:158–69.
[25] Yang YM, Shang DS, Zhao WD, Fang WG, Chen YH. Microglial TNP-α-dependent elevation of MHC class I expression on brain endothelium induced by amyloid-beta promotes T cell transendothelial migration. Neurochem Res 2013;38:2295–304.
[26] Zhou F. Molecular mechanisms of IFN-γ to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol 2009;28:239–60.
[27] Agrawal S, Kishore MC. MHC class I gene expression and regulation. J Hematother Stem Cell Res 2002;9:795–812.
[28] Mirzai A, Fujii N, Murakami T, Kiura K, Aoe K, Yamane H, et al. High frequency of allele-specific rotn-regulation of HLA class I expression in lung cancer cell lines. Anticancer Res 2004;24:1525–8.